使用左心室辅助装置降低固定性肺动脉高压后的长期心脏移植结局
该研究回顾性分析了79例终末期心力衰竭合并固定性肺动脉高压患者,经左心室辅助装置(LVAD)作为候选资格桥接后成功接受心脏移植,并与48例因非肺动脉高压原因接受LVAD桥接至移植的对照组比较。结果显示肺血管阻力从LVAD植入前的4.3±1.8 WU降至支持89天后的2.0±0.9 WU(P≤0.001),两组移植后长期生存率相当(log-rank P=0.585)。
要点
- LVAD作为候选资格桥接可逆转终末期心衰患者的固定性肺动脉高压。
- 肺血管阻力从4.3±1.8 WU降至2.0±0.9 WU(P≤0.001),中位支持89天。
- 研究组与对照组移植后3年、5年生存率相当(log-rank P=0.585)。
核心结论
- LVAD植入作为候选资格桥接可逆转终末期心力衰竭患者的固定性肺动脉高压。
- 移植后生存率优异,与移植登记时无固定性肺动脉高压的患者结果相当。
研究设计与样本
- 回顾性研究,纳入1998年10月至2016年9月在本中心使用6种不同LVAD装置成功桥接至心脏移植候选资格的79例终末期心力衰竭合并固定性肺动脉高压患者。
- 对照组为同一时间段内48例因非肺动脉高压原因接受LVAD桥接至移植后行心脏移植的患者。
- LVAD装置包括Novacor n=4、MicroMed DeBakey n=29、DuraHeart n=2、HeartMate II n=14、HVAD n=29和MVAD n=1;LVAD支持中位时间288天(范围45-2279天)。
主要发现
- 肺血管阻力在LVAD植入前为4.3±1.8 WU,经中位支持89天(四分位距4-156天)后降至2.0±0.9 WU(P≤0.001),随后患者被列入心脏移植名单。
- 研究组中2例(2.5%)在移植后出现急性右心衰竭,需要体外机械支持。
- 研究组移植后3年生存率83.5%、5年生存率81.0%,对照组分别为87.5%和85.4%,两组比较无显著差异(log-rank P=0.585)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Fixed pulmonary hypertension (fPH) is a contraindication for heart transplantation (HTX). Left ventricular assist device (LVAD) implantation as a bridge to candidacy can reverse fPH in patients with terminal heart failure by chronic left ventricular unloading. We report our institutional experience with terminal heart failure patients and fPH that were successfully bridged to candidacy and underwent subsequent HTX. METHODS: We retrospectively reviewed the data of 79 patients with terminal heart failure and fPH who were successfully bridged to candidacy for HTX with 6 different LVAD devices at our centre from October 1998 to September 2016 (Novacor n = 4, MicroMed DeBakey n = 29, DuraHeart n = 2, HeartMate II n = 14, HVAD n = 29 and MVAD n = 1). Median duration of LVAD support was 288 days (range 45-2279 days). Within the same timeframe, a control group of 48 patients underwent HTX after bridge-to-transplant LVAD therapy for reasons other than PH. Study end points were (i) development of fPH after LVAD implantation, (ii) post-transplant outcomes and (iii) incidence of severe adverse events. RESULTS: Pulmonary vascular resistance, assessed by vasodynamic catheterization, was 4.3 ± 1.8 WU before LVAD implantation. After a median support period of 89 days (interquartile range 4-156 days), pulmonary vascular resistance decreased to 2.0 ± 0.9 WU (P ≤ 0.001), and patients were listed for HTX. Median duration of LVAD support in the study group was 288 days (45-2279 days). We observed 2 patients (2.5%) with acute right heart failure who required extracorporeal mechanical support after HTX in the study group. Long-term post-transplant survival between the study group (3 years: 83.5%, 5 years: 81.0%) and the control group (3 years: 87.5%, 5 years: 85.4%) was comparable (log-rank: P = 0.585). CONCLUSIONS: LVAD implantation as a bridge to candidacy reverses fPH in patients with terminal heart failure. Post-HTX survival is excellent and comparable to results obtained in patients without fPH at the time of HTX listing.
引用
- Moayedifar R, Zuckermann A, Aliabadi-Zuckermann A, et al. Long-term heart transplant outcomes after lowering fixed pulmonary hypertension using left ventricular assist devices. Eur J Cardiothorac Surg. 2018. PMID: 29905775. doi:10.1093/ejcts/ezy214
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。